MARKET

ATNM

ATNM

Actinium Pharmac
AMEX
1.180
0.000
0.00%
After Hours: 1.200 +0.02 +1.69% 18:28 05/22 EDT
OPEN
1.180
PREV CLOSE
1.180
HIGH
1.190
LOW
1.160
VOLUME
73.39K
TURNOVER
--
52 WEEK HIGH
1.945
52 WEEK LOW
0.9520
MARKET CAP
37.02M
P/E (TTM)
-1.5687
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATNM last week (0511-0515)?
Weekly Report · 6d ago
Analyst Reiterates Buy on Actinium, Keeps $4 Price Target Amid Advancing Radiotherapy Pipeline and 2026–2027 Catalysts
TipRanks · 05/12 10:27
Weekly Report: what happened at ATNM last week (0504-0508)?
Weekly Report · 05/11 10:29
Weekly Report: what happened at ATNM last week (0427-0501)?
Weekly Report · 05/04 10:26
Weekly Report: what happened at ATNM last week (0420-0424)?
Weekly Report · 04/27 10:30
Reinforced Buy on Actinium: Strengthening ATNM-400 Pan-Tumor Data and Expanding Actimab-A AML Opportunities Drive Pipeline Upside
TipRanks · 04/22 16:15
Actinium presents data from Actimab-A studies at AACR
TipRanks · 04/22 11:29
Actinium presents preclinical results for ATNM-400 at AACR
TipRanks · 04/22 11:23
More
About ATNM
Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.

Webull offers Actinium Pharmaceuticals Inc stock information, including AMEX: ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.